ENTERPRISE 2 装置在颅内动脉瘤血管内治疗中的安全性和有效性 (EMPOWER)
ENTERPRISE 2 血管重建装置和输送系统注册:一项多中心、前瞻性、单臂观察研究,以评估该装置促进颅内动脉瘤血管内弹簧圈栓塞的安全性和有效性
The study is designed to evaluate the safety and effectiveness of ENTERPRISE 2 vascular reconstruction device and delivery system (hereinafter referred to as ENTERPRISE 2) to facilitate endovascular coil embolization of intracranial aneurysms.
研究概览
详细说明
This is a prospective, multicenter, single-arm observational study, in which enrolled patients will be implanted with the ENTERPRISE 2 for evaluation of safety and effectiveness of ENTERPRISE 2 in real-world applications.
The study population will consist of 164 patients with ruptured or unruptured intracranial aneurysms and a parent vessel diameter of ≥2.5 mm and ≤4 mm. All patients will be implanted with the study device.
The enrolled patients will be followed at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure.
The primary endpoint is the incidence of aneurysm recanalization (at 180 days) evaluated through digital subtraction angiography (DSA). Secondary effectiveness endpoints include incidence of aneurysm recanalization (at 1 year), successful stent/coil placement rate (immediately post procedure), aneurysm occlusion (immediately post procedure, at 180 days and 1 year), incidence of retreatment (at 30 and 180 days, and 1, 2, 3, 4 and 5 years). Safety evaluation include: incidence of disabling stroke or neurological death (at 180 days and 1 year), incidence of in-stent thrombosis (at 180 days and 1 year), and incidence of in-stent stenosis (at 180 days and 1 year). Exploratory endpoints include stent wall apposition performance (intra-procedure), first-time deployment success rate (intra-procedure) and duration of stent deployment (intra-procedure).
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100070
- Beijing Tiantan Hospital, Capital Medical University
-
Beijing、Beijing Municipality、中国、100029
- Beijing Anzhen Hospital, Capital Medical University
-
-
Guangdong
-
Guangzhou、Guangdong、中国
- Zhujiang Hospital of Southern Medical University
-
-
Henan
-
Zhengzhou、Henan、中国、450052
- The first affiliated hospital of Zhengzhou university
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210008
- Nanjing Drum Tower Hospital
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330006
- The first affiliated hospital of Nanchang university
-
-
Liaoning
-
Shenyang、Liaoning、中国、110004
- Shengjing Hospital of China Medical University
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国
- Huashan Hospital Shanghai Medical college, Fudan University
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310007
- Zhejiang Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
This study will be conducted in patients with unruptured or ruptured intracranial aneurysm with a parent vessel diameter of ≥2.5 mm and ≤4 mm.
描述
Inclusion Criteria:
- Patient (or his/her legal representative) understands the nature of the procedure and provides voluntary written informed consent for the use of his/her peri-procedural and follow-up data;
- Aged between 18 years and 80 years of age the time of consent;
- Patient has been diagnosed with ruptured (Hunt-Hess Grade I-III) or unruptured intracranial aneurysm and requires the endovascular treatment;
- Parent vessel with a diameter of ≥2.5 mm and ≤4 mm;
- Patient is willing to return to the investigational site for the post-procedure follow-up evaluations.
Exclusion Criteria:
- Severe co-morbidity associated with a life-expectancy of less than twelve months as determined by the investigator;
- Poor clinical condition with modified Rankin Scale (mRS) score ≥4;
- Having prior or potential severe allergic reaction to contrast medium;
- Known allergies to any of the device components, including Enterprise 2 and PROWLER® SELECT™ Plus Infusion Catheter;
- Angiogram demonstrating that the aneurysm is not appropriate for endovascular treatment (i.e. severe intracranial vessel tortuosity, stenosis, intracranial vasospasm not responsive to medical therapy);
- Arteriovenous malformation (AVM) in the territory of the target aneurysm;
- Unsuitable for the antithrombotic and/or anticoagulant therapies;
- Implantation of an intracranial stent associated with aneurysm or symptom distribution within 12 weeks prior to signature of Informed Consent Form;
- Implantation of a carotid stent associated with aneurysm or symptom distribution within 12 weeks prior to signature of Informed Consent Form;
- Evidence of active infection;
- Pregnant or lactating women;
- Having participated in clinical studies of other investigational drugs or devices within 30 days prior to signature of Informed Consent Form, excluding epidemiological studies of observational nature or natural history or not involving intervention;
- Pre-planned staged procedure of target aneurysms.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
ENTERPRISE 2 group
The study population enrolled for this clinical study is "aneurysm patients who need stent-assisted coiling treatment", using ENTERPRISE 2 device. |
The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of aneurysm recanalization
大体时间:at 180 days post procedure
|
Incidence of aneurysm recanalization (at 180 days) = number of target aneurysm recanalization (at 180 days) ÷ total number of target aneurysms receiving follow-up × 100%. The results of aneurysm angiography at 180-day follow-up will be obtained through DSA, and the post-procedure immediate aneurysm recanalization shown in angiograms will be graded as per the Raymond-Roy Classification Scale. The Raymond-Roy Classification at each follow-up time point increased by ≥ one class relative to that immediately after the procedure is defined as recanalization (e.g., Class I immediately after the procedure, Class II at 180-day follow-up). |
at 180 days post procedure
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of aneurysm recanalization
大体时间:at 1 year post procedure
|
Incidence of aneurysm recanalization (at 1 year) = number of target aneurysm recanalization (at 1 year) ÷ total number of target aneurysms receiving follow-up × 100%. The results of aneurysm angiography at 1 year follow-ups will be obtained through DSA or MRA or CTA. |
at 1 year post procedure
|
|
Successful stent/coil placement rate
大体时间:immediately post procedure
|
Successful stent/coil placement rate = number of target aneurysms with successful stent/coil placement ÷ total number of target aneurysms× 100%. Successful stent/coil placement is defined as successful stent deployment and successful delivery and placement of the coil at the target aneurysm assessed immediately post procedure through angiography. |
immediately post procedure
|
|
Aneurysm occlusion
大体时间:immediately post procedure, at 180 days and at 1 year post procedure
|
Aneurysm occlusion rate = number of target aneurysms with Raymond-Roy Class I or II aneurysm occlusion÷ total number of target aneurysms× 100%. The aneurysm occlusion will be assessed by classifying the post-procedure immediate aneurysm occlusion shown in angiograms based on the Raymond-Roy Classification. |
immediately post procedure, at 180 days and at 1 year post procedure
|
|
Incidence of retreatment
大体时间:at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure
|
Incidence of retreatment = number of target aneurysms receiving retreatment during the follow-up ÷ total number of target aneurysms receiving follow-up ×100%. Retreatment refers to any intervention to the target aneurysm after completing first stent-assisted coil embolization for the target aneurysm. |
at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of disabling stroke or neurological death
大体时间:at 180 days, at 1 year post procedure
|
Incidence of disabling stroke or neurological death = number of patients with disabling stroke or neurological death ÷ total number of patients receiving follow-up × 100%. Stroke is defined as rapidly developing clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours with no apparent cause other than of vascular origin, including ischemic stroke or hemorrhagic stroke (i.e., intraparenchymal hemorrhage (IPH), SAH, subdural hemorrhage (SDH), epidural hemorrhage (EDH)). Disabling stroke is defined as mRS score ≥ 3 assessed at a minimum of 90 days (+/- 30 days) post-stroke event. Neurological death, also called brain death, refers to irreversible loss of the capacity for consciousness combined with the irreversible loss of all brainstem functions, including the capacity to breathe. |
at 180 days, at 1 year post procedure
|
|
Incidence of in-stent thrombosis
大体时间:at 180 days, at 1 year post procedure
|
Incidence of in-stent thrombosis = number of target aneurysms with parent vessel (in-stent) thrombosis during follow-up ÷ total number of target aneurysms receiving follow-up ×100%. |
at 180 days, at 1 year post procedure
|
|
Incidence of in-stent stenosis
大体时间:at 180 days, at 1 year post procedure
|
Incidence of in-stent stenosis = number of target aneurysms with parent vessel (in-stent) stenosis during follow-up ÷ total number of target aneurysms receiving follow-up ×100%. Mild, moderate, and severe in-stent stenosis is clinically defined as a stenosis of <33%, 33-67%, and ≥67%, respectively, comparing with non-stented parent vessel [43, 44]. In this study, moderate and severe in-stent stenoses (with a stenosis of ≥33%) of the parent vessel are defined as in-stent stenosis. |
at 180 days, at 1 year post procedure
|
合作者和调查者
调查人员
- 首席研究员:Xinjian Yang, Professor、Beijing Tiantan Hospital
- 首席研究员:Shiqing Mu, Professor、Beijing Tiantan Hospital
- 首席研究员:Qingrong Zhang, Professor、The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- 首席研究员:Yuxiang Gu, Professor、Huashan Hospital Shanghai Medical college, Fudan University
- 首席研究员:Chuanzhi Duan, Professor、Southern Medical University, China
- 首席研究员:Shu Wan, Professor、Zhejiang Hospital
- 首席研究员:Bo Yu, Professor、Shengjing Hospital
- 首席研究员:Yang Wang, Professor、The First Affiliated Hospital of Nanchang University
- 首席研究员:Sheng Guan, Professor、The First Affiliated Hospital of Zhengzhou University
- 首席研究员:Wohua Zhao, Professor、Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
- 首席研究员:Xinjian Yang, Professor、Beijing Anzhen Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- CNV_2018_02
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Johnson & Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.